ChemLifeIntel
Access

Rompe Pecho MAX Multi Symptoms

TRACKED

CASHSN
THERAPEUTIC AREAS
MOLECULE INTELLIGENCE SNAPSHOTlive
14
Manufacturers monitored
38
Intelligence briefs
3
Active regulatory actions
₹2,800 Cr
Est. India export value

INTELLIGENCE

Showing 1 of 1 briefs for Rompe Pecho MAX Multi Symptoms
REGULATORY INTELLIGENCE·Warning Letter

FDA Class II Recall: Efficient Laboratories' Rompe Pecho MAX Multi Symptoms Due to Microbial Contamination Signals Heightened Regulatory Scrutiny

Efficient Laboratories, Inc. initiated a Class II recall of 4,080 bottles of Rompe Pecho MAX Multi Symptoms due to microbial contamination. This event, terminated in October 2020, underscores critical compliance risks for non-sterile products. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar supply chain disruptions and ensure patient safety.

90-Day Activity
CMCatherine Morrow· Senior Regulatory Intelligence Analyst
2020-02-19